Ilaria Conti

3.0k total citations · 2 hit papers
47 papers, 1.9k citations indexed

About

Ilaria Conti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ilaria Conti has authored 47 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Ilaria Conti's work include Parvovirus B19 Infection Studies (6 papers), Sarcoma Diagnosis and Treatment (6 papers) and Asthma and respiratory diseases (5 papers). Ilaria Conti is often cited by papers focused on Parvovirus B19 Infection Studies (6 papers), Sarcoma Diagnosis and Treatment (6 papers) and Asthma and respiratory diseases (5 papers). Ilaria Conti collaborates with scholars based in Italy, United States and United Kingdom. Ilaria Conti's co-authors include Barrett J. Rollins, Damien M. Cronier, Luca M. Neri, Carolina Simioni, Gabriele Varano, Robert Ilaria, William D. Tap, Robin L. Jones, Bartosz Chmielowski and Jan Cosaert and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Ilaria Conti

45 papers receiving 1.9k citations

Hit Papers

Olaratumab and doxorubici... 2016 2026 2019 2022 2016 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    2016 436 citations William D. Tap, Robin L. Jones et al. The Lancet profile →
  2. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
    2018 372 citations Yu Jeong Bang, Eduardo Yañez Ruiz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ilaria Conti Italy 19 976 786 424 352 230 47 1.9k
Laurent Alberti France 23 656 0.7× 982 1.2× 534 1.3× 222 0.6× 194 0.8× 48 1.9k
Virginia Ferraresi Italy 25 1.3k 1.3× 1.0k 1.3× 635 1.5× 370 1.1× 219 1.0× 125 2.4k
Giuseppe Badalamenti Italy 25 1.0k 1.0× 764 1.0× 621 1.5× 182 0.5× 441 1.9× 144 2.3k
Nicholas E. Papadopoulos United States 28 1.4k 1.5× 706 0.9× 870 2.1× 484 1.4× 286 1.2× 82 2.4k
Hideya Takeuchi Japan 17 584 0.6× 358 0.5× 371 0.9× 314 0.9× 223 1.0× 70 1.3k
Fabio Bozzi Italy 21 526 0.5× 662 0.8× 602 1.4× 646 1.8× 101 0.4× 49 1.9k
Jia-Lin Lee South Korea 21 892 0.9× 503 0.6× 919 2.2× 146 0.4× 335 1.5× 50 2.0k
Bernadette Liegl‐Atzwanger Austria 25 863 0.9× 1.3k 1.6× 335 0.8× 118 0.3× 528 2.3× 109 2.2k
Akin Atmaca Germany 24 2.2k 2.2× 1.4k 1.8× 845 2.0× 505 1.4× 565 2.5× 61 3.3k

Countries citing papers authored by Ilaria Conti

Since Specialization
Citations

This map shows the geographic impact of Ilaria Conti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilaria Conti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilaria Conti more than expected).

Fields of papers citing papers by Ilaria Conti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilaria Conti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilaria Conti. The network helps show where Ilaria Conti may publish in the future.

Co-authorship network of co-authors of Ilaria Conti

This figure shows the co-authorship network connecting the top 25 collaborators of Ilaria Conti. A scholar is included among the top collaborators of Ilaria Conti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilaria Conti. Ilaria Conti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Conti, Ilaria, Rita Morigi, Alessandra Locatelli, et al.. (2019). Synthesis of 3-(Imidazo[2,1-b]thiazol-6-yl)-2H-chromen-2-one Derivatives and Study of Their Antiviral Activity against Parvovirus B19. Molecules. 24(6). 1037–1037. 19 indexed citations
4.
Jones, Robin L., Gary Mo, John R. Baldwin, et al.. (2018). Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. Cancer Chemotherapy and Pharmacology. 83(1). 191–199. 9 indexed citations
5.
Bua, Gloria, Ilaria Conti, Elisabetta Manaresi, et al.. (2018). Antiviral activity of brincidofovir on parvovirus B19. Antiviral Research. 162. 22–29. 19 indexed citations
6.
Bang, Yu Jeong, Eduardo Yañez Ruiz, Eric Van Cutsem, et al.. (2018). Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Annals of Oncology. 29(10). 2052–2060. 372 indexed citations breakdown →
7.
Mo, Gary, John R. Baldwin, Debra Luffer‐Atlas, et al.. (2017). Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer. Clinical Pharmacokinetics. 57(3). 355–365. 21 indexed citations
8.
Manaresi, Elisabetta, Ilaria Conti, Gloria Bua, Francesca Bonvicini, & Giorgio Gallinella. (2017). A Parvovirus B19 synthetic genome: sequence features and functional competence. Virology. 508. 54–62. 14 indexed citations
9.
Chen, Shih-Hsun, Youyan Zhang, Robert D. Van Horn, et al.. (2016). Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discovery. 6(3). 300–315. 117 indexed citations
10.
Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2016). Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 22(23). 5688–5695. 22 indexed citations
11.
Chen, Xuguang, Yunyue Wang, David Nelson, et al.. (2016). CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice. PLoS ONE. 11(11). e0165595–e0165595. 44 indexed citations
12.
Raje, Noopur, Philippe Moreau, Evangelos Terpos, et al.. (2016). Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology. 176(5). 783–795. 38 indexed citations
13.
Tap, William D., Robin L. Jones, Brian A. Van Tine, et al.. (2016). Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. The Lancet. 388(10043). 488–497. 436 indexed citations breakdown →
14.
15.
Jones, Robin L., Gary Mo, John R. Baldwin, et al.. (2016). Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients. Annals of Oncology. 27. vi485–vi485. 1 indexed citations
16.
Conti, Ilaria, Francesco Calderaro, Luisa Beltran, et al.. (2008). Multicentre Evaluation of the Second Generation Elecsys NT-proBNP Assay. 32(5). 458–458. 3 indexed citations
17.
Conti, Ilaria, et al.. (2004). Chemokine‐Based Pathogenetic Mechanisms in Cancer. Novartis Foundation symposium. 256. 29–48. 10 indexed citations
18.
Vagaggini, Barbara, M. Taccola, Ilaria Conti, et al.. (2001). Budesonide Reduces Neutrophilic but Not Functional Airway Response to Ozone in Mild Asthmatics. American Journal of Respiratory and Critical Care Medicine. 164(12). 2172–2176. 37 indexed citations
19.
Dente, Federico L., Elena Bacci, A. Di Franco, et al.. (2000). Reproducibility of early and late asthmatic responses to allergen challenge in a large group of asthmatics. Respiratory Medicine. 94(5). 441–447. 13 indexed citations
20.
Bancalari, L, Ilaria Conti, Daniela Giannessi, et al.. (1999). Early increase in urinary leukotriene E4 (LTE4) is dependent on allergen dose inhaled during bronchial challenge in asthmatic subjects. Allergy. 54(12). 1278–1285. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurent Alberti Breakdown of academic impact, for papers by Virginia Ferraresi Breakdown of academic impact, for papers by Giuseppe Badalamenti Breakdown of academic impact, for papers by Nicholas E. Papadopoulos Breakdown of academic impact, for papers by Hideya Takeuchi Breakdown of academic impact, for papers by Fabio Bozzi Breakdown of academic impact, for papers by Jia-Lin Lee Breakdown of academic impact, for papers by Bernadette Liegl‐Atzwanger Breakdown of academic impact, for papers by Akin Atmaca
Rankless by CCL
2026